Rhythm Biosciences Limited (RHY.AX) Stock Analysis & Winston Score

Rhythm Biosciences is a small Australian biotech company focused on developing blood tests that can detect cancer early. Its main product is ColoSTAT, a colorectal cancer screening test designed to identify the disease from a simple blood sample rather than requiring more invasive procedures. The company sells to healthcare providers and targets patients who need routine colorectal cancer screening. Rhythm Biosciences makes money by selling its diagnostic tests, though it is currently in an early commercial stage and spends far more than it earns. It operates primarily in Australia and is a very small company with a market cap under $10 million. The deeply negative margins shown in its financials reflect a pre-revenue or near-zero-revenue business that is still burning cash to fund development and commercialization. The key risk is whether the company can generate enough sales traction and secure additional funding before exhausting its cash reserves.